![Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial - The Lancet Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial - The Lancet](https://www.thelancet.com/cms/attachment/5a3c1320-5d4d-42ba-bed6-e1060fa2102b/gr1.gif)
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial - The Lancet
![Antoine ABOU FAYAD | Assistant Professor | PhD in Bioorganic Chemistry | American University of Beirut, Beirut | AUB | Department of Experimental Pathology, Microbiology, and Immunology | Research profile Antoine ABOU FAYAD | Assistant Professor | PhD in Bioorganic Chemistry | American University of Beirut, Beirut | AUB | Department of Experimental Pathology, Microbiology, and Immunology | Research profile](https://i1.rgstatic.net/ii/profile.image/902987673247744-1592300446682_Q512/Antoine-Abou-Fayad.jpg)
Antoine ABOU FAYAD | Assistant Professor | PhD in Bioorganic Chemistry | American University of Beirut, Beirut | AUB | Department of Experimental Pathology, Microbiology, and Immunology | Research profile
![Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial - The Lancet Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial - The Lancet](https://www.thelancet.com/cms/asset/10e1989d-d781-4363-9ec6-0acbc75cf444/gr1.jpg)